Clinical trials
Prostate cancer clinical trials
Cancer of the prostate gland, one of the most common cancers in men. We’re tracking 1,212 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06682390Recruiting
Race and diet study for men on hormone therapy
This study explores how race affects nutrition for men receiving hormone therapy (ADT) for prostate cancer. It may help researchers understand if different dietary approaches are needed based on race.
Los Angeles, CaliforniaAges 18 years+ - NCT05802121RecruitingEarly Phase 1
Testing a gut bacteria supplement side effects during prostate hormone therapy
This early-phase study looks at how changing gut bacteria (especially Akkermansia) affects metabolic side effects in men starting prostate hormone therapy (ADT). It may help researchers understand how to reduce or manage side effects for people on ADT.
London, OntarioAges 18 years+ - NCT06636123RecruitingPhase 1
Testing GZ17-6.02 for advanced prostate cancer after hormone therapy
This trial tests a new drug combination (GZ17-6.02) for men with advanced prostate cancer that has stopped responding to standard hormone therapies. The goal is to see if the drug can help slow down the cancer.
Richmond, VirginiaAges 18 years+ - NCT06241846RecruitingPhase 2
Study of YL201 for advanced prostate cancer that has spread and stopped responding to hormone therapy
This trial tests a new drug, YL201, in men with advanced prostate cancer that has spread and is no longer controlled by standard hormone therapy. The goal is to see if YL201 can shrink tumors or slow the cancer's growth.
Hefei, AnhuiAges 18 years+ - NCT05649943Recruiting
New prostate cancer treatment plus local therapy for metastatic cases
This trial studies whether adding apalutamide to standard hormone therapy (ADT) improves outcomes for men with metastatic hormone-sensitive prostate cancer. Some people may also receive local treatments (like surgery or radiotherapy) to control the prostate and nearby areas.
Milan, LombardyAges 18 years+ - NCT06514521Recruiting
Study of Pluvicto for prostate cancer in Korea
This study is for men with prostate cancer who are being treated with or are scheduled to receive the drug Pluvicto in South Korea. It aims to track real-world results and safety.
Seongnam-si, Gyeonggi-doAges 18–100 - NCT06520345RecruitingPhase 3
A new treatment for advanced prostate cancer that has stopped responding to hormone therapy
This trial tests a new radioactive drug (177Lu-TLX591) plus standard care against standard care alone for men with metastatic castration-resistant prostate cancer that has progressed on an androgen receptor pathway inhibitor. The goal is to see if this targeted radiation can help control the cancer.
Orange, CaliforniaAges 18 years+ - NCT06496256Recruiting
Barrigel gel for radiation after prostate removal
This trial tests a gel placed in the rectum during radiation therapy to protect healthy tissue after prostate removal. It is for men whose prostate cancer has come back (PSA rise) and who need radiation to the prostate bed.
Chandler, ArizonaAges 18 years+ - NCT06492122RecruitingPhase 1
Study of a radioactive drug for advanced prostate cancer
This trial tests a new radioactive treatment, [225Ac]Ac-FL-020, for men with metastatic castration-resistant prostate cancer (mCRPC) that has gotten worse despite other treatments. It's for those who have had at least one prior hormone therapy or chemotherapy.
Duarte, CaliforniaAges 18 years+ - NCT06469710Recruiting
Collecting cancer cells from blood in metastatic prostate cancer
This trial is testing a blood-filtering procedure (leukapheresis) to collect special cancer cells that have broken away from the tumor. It may help doctors better understand your prostate cancer and guide future treatment.
ShanghaiAges 18–75 - NCT06450106RecruitingPhase 1
STM-416p injection during prostate removal surgery
This trial tests an injection called STM-416p given during prostate removal surgery to see if it can help prevent prostate cancer from coming back. It may be an option for men with intermediate to high-risk prostate cancer who are already planning to have their prostate removed.
Tucson, ArizonaAges 18 years+ - NCT06450548Recruiting
PSMA and FDG PET scans before 177Lu-PSMA therapy
This trial uses two types of PET scans (PSMA and FDG) to see how well a radioactive therapy called 177Lu-PSMA might work for men with advanced prostate cancer that has stopped responding to hormone therapy and chemotherapy.
RouenAges 18 years+ - NCT06363435Recruiting
AI study of tumor burden on PSMA PET-CT scans
This trial tests an AI tool that measures tumor burden on PSMA PET-CT scans. If you are having this scan for prostate cancer, it could help doctors get more detailed information from your images.
LundAges 20–120 - NCT06353321Recruiting
PSMA-PET imaging for guiding radiation therapy in prostate cancer
This study tests a new way to use a PSMA-PET scan (a special imaging test that finds prostate cancer cells) to guide a type of radiation treatment called BgRT. It is for men with prostate cancer who are already getting a PSMA-PET scan as part of their regular care.
Dallas, TexasAges Any age - NCT06303622Recruiting
Comparing two MRI-guided biopsy methods for prostate cancer
This trial compares two ways to guide a prostate biopsy using MRI images, to see which better detects clinically significant prostate cancer in men with suspicious MRI findings.
Hong KongAges 18 years+ - NCT06262139RecruitingPhase 1/Phase 2
New MRI dye for high-risk prostate cancer
This trial tests a new MRI contrast dye that might help doctors see aggressive prostate cancer more clearly. It is for men with high-risk prostate cancer (Gleason 8-10) who have already had an MRI and a biopsy.
Atlanta, GeorgiaAges 18–90 - NCT06237179RecruitingPhase 1/Phase 2
Exercise program to reduce heart risk in prostate cancer
This study tests whether a supervised exercise program can help reduce heart disease risk in men with prostate cancer who are on hormone therapy. Participants will exercise at home or in a group and be monitored for heart health changes.
Richmond, VirginiaAges 40–85 - NCT06200558Recruiting
Study of treatments for advanced prostate cancer
This study looks back at the experiences of men with prostate cancer that has spread to other parts of the body. It aims to learn which treatments—such as hormone therapy combined with other drugs, or a radioactive therapy—work best for different types of advanced prostate cancer.
Province of Macerata, MacerataAges 18 years+ - NCT06163924Recruiting
Heart risk reduction in prostate cancer patients on hormone therapy
This study tests whether a team of doctors, nurses, and other specialists can help reduce the risk of heart problems in men with prostate cancer who are on hormone therapy (ADT). It focuses on providing extra support for heart health.
Hong KongAges 18–80 - NCT06155084RecruitingPhase 1/Phase 2
HP518 for advanced prostate cancer that has spread
This trial tests an oral drug called HP518 for men with a specific genetic change in their prostate cancer that has spread and stopped responding to standard hormone therapy and chemotherapy. The goal is to see if HP518 can control the cancer.
Hefei, AnhuiAges 18 years+ - NCT06136624RecruitingPhase 3
Comparing a new drug to standard hormone therapy for advanced prostate cancer
This trial tests a new pill, opevesostat, against other hormone treatments for men with metastatic castration-resistant prostate cancer that has progressed after previous therapies. It aims to see which approach works better.
Orange, CaliforniaAges 18 years+ - NCT06111313RecruitingPhase 2
Prostate cancer trial testing targeted radiation with hormone therapy
This trial tests a new radiation approach for prostate cancer that has not spread. It combines different types of radiation with or without hormone therapy to see if this approach works better with fewer side effects.
Miami, FloridaAges 35–85 - NCT06084338RecruitingPhase 2
Focused Radiation Therapy Without Hormone Therapy for Advanced Prostate Cancer
This trial tests whether giving focused radiation to many cancer spots (SBRT) can work without using testosterone-blocking hormone therapy. It is for men whose prostate cancer has spread and is no longer responding to low testosterone, and who have already tried one of the newer hormone drugs.
West Los Angeles, CaliforniaAges 18 years+ - NCT06101290Recruiting
Local therapy for progressing spots in genitourinary cancers
This trial explores whether treating only the new or growing spots of cancer (called oligoprogression) with local therapies like radiation or ablation can help you stay on your current systemic treatment longer. It is for people with prostate, bladder, or kidney cancer that has started to progress in a few places.
Sacramento, CaliforniaAges 18 years+
Hear when a new Prostate cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostate cancer?
- Yes. Clin2 currently lists 1,212 recruiting prostate cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.